Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Brain Neoplasms 6Glioblastoma 5Prostatic Neoplasms 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Childhood Brain Neoplasm 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pancreatic carcinoma, familial 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Neurodegenerative Diseases 1Neoplasms 1Malignant Solid Neoplasm 1Lung Carcinoma Metastatic in the Brain 1Liver Neoplasms 1Liver Cirrhosis 1Kidney Neoplasms 1

Interventions

pembrolizumab 1Magnetic Resonance Spectroscopy 1Ferrosoferric Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Carcinoma Metastatic in the Brain × Ferrosoferric Oxide × Clear all
NCT03325166 2022-08-10

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled 8 charts

Lung Carcinoma Metastatic in the Brain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡